Ikonisys Revenue and Competitors

Location

N/A

Total Funding

Analytics

Industry

Estimated Revenue & Valuation

  • Ikonisys's estimated annual revenue is currently $4.8M per year.(i)
  • Ikonisys's estimated revenue per employee is $112,000

Employee Data

  • Ikonisys has 43 Employees.(i)
  • Ikonisys grew their employee count by -4% last year.

Ikonisys's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Director OperationsReveal Email/Phone
5
Chief Commercial Officer (CCO)Reveal Email/Phone
6
Sr. Lead Research Scientist @ Ikonisys, Inc.Reveal Email/Phone
7
Senior Pathology Scientific Procedure ConsultantReveal Email/Phone
8
Lead Technical EngineerReveal Email/Phone
9
Sales Director, USReveal Email/Phone
10
Master Thesis StudentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.6M90-36%$14.1MN/A
#2
$83.2M468-3%$251MN/A
#3
$14M1001%N/AN/A
#4
$14.6M0N/A$12.5MN/A
#5
$30.3M197-6%N/AN/A
#6
$0.1M6-25%$2.6MN/A
#7
$45.1M2932%N/AN/A
#8
$4.8M43-7%N/AN/A
#9
$399.3M203740%N/AN/A
#10
$44M2864%N/AN/A
Add Company

What Is Ikonisys?

Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease. Through its breakthrough fluorescence microscopy platform, Ikonisys continues to develop a stream of oncology tests for a variety of cancers. At the center of the platform is the Ikoniscope®, a robotic, high-throughput, microscopy system that provides a true “walk away” automated solution. In addition to providing high quality cell images, the platform analyzes the cells of interest, offering an interpretation of the analysis, to facilitate the quick, accurate reporting of the test result. In addition to automating traditional FISH-based tests, the rare cell detection and analysis capabilities of the platform, that facilitates the examination of large complex samples for the clinically relevant cells, make it particularly suitable for circulating tumor cell-based testing.

keywords:N/A

N/A

Total Funding

43

Number of Employees

$4.8M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.5M43-17%N/A
#2
$6M438%N/A
#3
$5M430%N/A
#4
$11.4M43-28%$60.6M
#5
$7.8M43-61%N/A